Bipolar Disorder News

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.

While psychedelic use may be associated with fewer psychotic symptoms among adolescents, the link between psychedelics and manic symptoms appears to be associated with genetic vulnerability to schizophrenia or bipolar disorder, data show.

Individuals with mania who were admitted to an acute care psychiatric unit saw greater sleep improvement than patients with major depressive disorder, according to a study.

A single, 25 mg dose of synthetic psilocybin along with psychotherapy was safe and effective among individuals with bipolar II disorder depression, supporting further study of psychedelics for these patients, according to research.

NEW ORLEANS — Former NFL wide receiver and longtime mental health advocate Brandon Marshall emphasized the importance of maintaining mental health and shared his methods for staying mentally “fit.”

A study of more than 110,000 patients receiving psychotherapy found improved continuity of care and significantly fewer days between appointments after the switch to virtual care during the COVID-19 pandemic.

Mental health conditions affect one in eight people and one in seven adolescents worldwide, according to WHO.

A potential new lithium treatment for bipolar disorder, designed to avoid toxicities currently associated with the substance, is set to undergo a phase 2 study.

Published results showed no statistically significant associations between mental health conditions, such as depression, anxiety, bipolar disorder, trauma and schizophrenia, and outcomes after total joint arthroplasty.

Factors previously associated with short-term risk for new-onset bipolar disorder also were associated with significantly higher risk after more than 10 years of follow-up, according to a study published in JAMA Network Open.